View Future GrowthKDventures 과거 순이익 실적과거 기준 점검 0/6KDventures 의 수입은 연평균 -48.3%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 8.8%의 비율로 증가했습니다. 매출은 연평균 6%의 비율로 감소해 왔습니다.핵심 정보-48.31%순이익 성장률-47.12%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률7.33%매출 성장률-6.04%자기자본이익률-19.35%순이익률-13,678.69%다음 순이익 업데이트28 Aug 2026최근 과거 실적 업데이트공시 • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.공시 • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year.모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Karl Anders Harfstrand was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 07KDventures AB, Annual General Meeting, May 12, 2026KDventures AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: nanna svartz vag 2, 171 65 solna, solna Sweden공시 • Mar 03KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian SyndromeKDventures AB announced that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition. In 2021, Organon acquired KDventures' portfolio company Forendo, but in July 2025 discontinued development of OG-6219, its most advanced drug candidate targeting endometriosis. The acquisition also included a preclinical drug candidate for polycystic ovary syndrome. Organon has now announced that development of this drug candidate has also been discontinued. This announcement means that the value of KDventures' share of the parties’ agreement on potential additional purchase considerations will be written off in its entirety, which will be reported in the interim report for the first quarter of 2026.공시 • Jan 29Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 384,166,664 Price\Range: SEK 0.3 Transaction Features: Rights Offering공시 • Dec 01Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 675,193,985 Price\Range: SEK 0.3 Transaction Features: Rights Offering공시 • Nov 05Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemiaKarolinska Development AB announced that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in fourth quarter of 2025, in line with the company's development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of The company's phase 2 study with sevuparin in patients with chronic kidney disease with anemic. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated.공시 • Sep 04Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million. Security Name: Shares Security Type: Common Stock Transaction Features: Rights Offering공시 • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026공시 • Jun 30An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025.공시 • Apr 08Karolinska Development AB (publ), Annual General Meeting, May 15, 2025Karolinska Development AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at nanna svartz vag 2, 17165 solna, Sweden공시 • Dec 19Karolinska Development AB Announces Changes to ChairmanKarolinska Development AB announced that its Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also Head of Global Business Development at Sino Pharmaceuticals Limited, CEO at invoX Pharma Limited and Director at Softhale BV and pHion Therapeutics.공시 • Dec 11Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the BoardKarolinska Development AB announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting.Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.공시 • Nov 15Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF VaccinesKarolinska Development AB announced that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15, 2024, as Dr Richard Bethell has decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role. Dr. Gaston Picchio has over 30 years of experience in clinical virology from his previous roles at the Scripps Research Institute, Johnson & Johnson, and Arbutus Biopharma. While at Johnson & Johnson, Dr. Picchio was involved in the development and approval of antivirals and vaccines for HIV, HCV, and Zika. Most recently, he comes from Arbutus Biopharma, where he led the development of novel therapeutic combinations aimed at curing chronic hepatitis B.공시 • Sep 23An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024. An undisclosed buyer completed the acquisition of 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024.Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.공시 • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 72% per year for the foreseeable future. Revenue is less than US$1m (kr1.9m revenue, or US$184k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€36.7m market cap, or US$39.9m).Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.공시 • Apr 16Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-ElectionKarolinska Development AB (publ) announced that Björn Cochlovius has declined re-election.Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year.New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$191k). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€37.5m market cap, or US$40.5m).Recent Insider Transactions • Feb 28Chief Executive Officer recently bought €7.2k worth of stockOn the 19th of February, Viktor Drvota bought around 50k shares on-market at roughly €0.14 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Viktor's only on-market trade for the last 12 months.Reported Earnings • Feb 18Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.공시 • Feb 03+ 5 more updatesKarolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024Karolinska Development AB (publ) announced that they will report first half, 2024 results on Aug 30, 2024New Risk • Nov 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 67% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 67% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$194k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€38.3m market cap, or US$41.8m).공시 • Nov 09Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,150,000 Price\Range: SEK 2 Transaction Features: Rights Offering공시 • Sep 21Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal SurgeryKarolinska Development AB announced that its portfolio company OssDsign has received clearance from FDA for the use of OssDsign Catalyst in interbody cages in spinal surgery. The FDA clearance creates possibilities in a new indication with major market potential for the company's innovative nanosynthetic bone graft. The clearance from the U.S. Food and Drug Administration (FDA) allows surgeons to use the OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone. The decision by the FDA is based on OssDsign's outstanding bone regeneration results which surpass other synthetic bone grafts in challenging evaluation models.Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.086 (up from kr0.083 loss in 2Q 2022). Net income: kr23.3m (up kr45.6m from 2Q 2022). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.Reported Earnings • Mar 28Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr0.34 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 4.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 18Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr3.43 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 7.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.5%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.공시 • Feb 15Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive DataKarolinska Development AB (publ) announced that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate tafoxiparin has resulted in further positive data. The extension of the study met its objective, which was to evaluate if the efficacy of tafoxiparin obtained in the phase 2b trial persists when the drug is administered in additional doses. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. The completed extension of the phase 2b study included a total of 164 women, and the results show that the cervical ripening effect persists in the study. In addition, a clear dose-response relationship was observed. Up to 30% of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child, leading to high healthcare costs. Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%.Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr46.6m (loss widened kr45.4m from 3Q 2021). Revenue is expected to decline by 3.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.9%.공시 • Nov 19+ 1 more updateKarolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023Karolinska Development AB (publ) announced that they will report first half, 2023 results on Aug 25, 2023공시 • Nov 18Karolinska Development AB (publ), Annual General Meeting, May 16, 2023Karolinska Development AB (publ), Annual General Meeting, May 16, 2023.Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr22.3m (down 110% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 8.1% compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.공시 • Aug 19+ 2 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Karolinska Development AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr29.2m (loss widened 17% from 1Q 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 8.1% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.공시 • Apr 26Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion StudyKarolinska Development AB (publ) announced that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. OssDsign will now follow the patients recruited for the study for 24 months. The outcome of the study will primarily focus on healing between the vertebrae and the lack of treatment-related side effects. The company’s nanosynthetic bone graft OssDsign Catalyst received FDA approval in 2020 and was launched on the US market in August 2021. Karolinska Development's shareholding in OssDsign AB, including indirect ownership via KCIF Co-Investment Fund, amounts to 10.4%.Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 7.8% compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.공시 • Feb 08Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 93,360,022 Price\Range: SEK 4 Security Name: Class A Shares Security Type: Common Stock Securities Offered: 1,052,163 Price\Range: SEK 4 Transaction Features: Rights Offering공시 • Dec 14Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.Organon & Co. (NYSE:OGN) agreed to acquire Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others for approximately $950 million on November 11, 2021. Under the agreement, Organon & Co. shall make an initial payment of $75 million. In addition, there are conditional payments totaling $270 million linked to milestones in the development and registration processes for the company's drug candidates, and additional payments totaling $600 million linked to commercial milestones. The completion of the transaction is subject to review by competition authorities and other customary conditions. The transaction is expected to close in December 2021. Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others on December 11, 2021. The consideration for the transaction includes a $75 million upfront payment, assumption of approximately $9 million of Forendo debt, payments upon the achievement of certain development and regulatory milestones of up to $270 million and commercial milestones payments of up to $600 million, which together could amount to total consideration of $954 million. Moelis & Company acted as exclusive financial advisor to Forendo.공시 • Dec 02Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate SevuparinKarolinska Development AB (publ) announced that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of sevuparin. The drug candidate is being developed as a potential treatment for sepsis/septic shock, a serious and often fatal condition. The randomized, placebo-controlled Phase 1b study will evaluate the effect of sevuparin on symptoms in healthy individuals injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and in the blood (systemic inflammation). Provocation with LPS is a well-established experimental model to characterize the early stages of septic inflammation by eliciting measurable symptoms. In addition, the study will evaluate the safety profile of sevuparin when used in combination with standard prophylactic blood-thinning heparin therapy.Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr1.20m (loss narrowed 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 174% share price gain to €1.13, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 79% over the past three years.Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)Second quarter 2021 results: Net income: kr216.4m (up kr214.3m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.공시 • Aug 13Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical ProgramKarolinska Development AB announced that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics clinical program evaluating eprenetapopt with acalabrutinib or venetoclax and rituximab in lymphoid malignancies. The issue means there will be a pause in the patient enrollment until the agency reverses the decision. Patients previously enrolled and showing positive clinical responses will continue to receive study treatment. Aprea Therapeutics was initially notified of a partial hold in the myeloid malignancy clinical program and shortly thereafter received notification from the FDA that a clinical hold had also been issued in the ongoing lymphoid malignancy study. The agency's decision is related to the safety and efficacy data presented in a recent Phase 3 study of eprenetapopt in TP53-mutaed myelodysplastic syndrome (MDS). Aprea Therapeutics intends to work in close dialogue with the FDA to clarify and address the agency's concerns in order to resume activity in the clinical trial program as soon as possible. Karolinska Development has an interest in Aprea Therapeutics through KDev Investment amounting to a total holding of 8.4% of the outstanding shares in Aprea Therapeutics.공시 • Jun 18Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.Karolinska Development AB (publ) (OM:KDEV) acquired 21% stake in Anacardio AB on June 17, 2021. The consideration received under the transaction is intended to cover costs for necessary activities prior to a planned major capital raising to finance the first part of the project's clinical development. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 21% stake in Anacardio AB on June 17, 2021.Reported Earnings • May 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr24.9m (loss narrowed 80% from 1Q 2020).Reported Earnings • Mar 31Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).Executive Departure • Mar 10CFO & Deputy CEO Fredrik Jarrsten has left the companyOn the 7th of March, Fredrik Jarrsten, was replaced as CEO by Viktor Drvota. As of December 2020, Fredrik personally held only 120.00k shares (€19k worth at the time). A total of 5 executives have left over the last 12 months.공시 • Mar 03+ 1 more updateKarolinska Development AB Announces CFO ChangesKarolinska Development AB announced that Per Aniansson has been appointed as new CFO. He has extensive experience in investments, business development and financing of high-growth companies in the life science industry. Per Aniansson takes up the position on March 7 and will initially work part-time (50%) in the company. He replaces Fredrik Järrsten, who has chosen to move on to a leading position within another life science company. Per Anainsson (b. 1966), Master of Science in Engineering and MBA, has over 20 years of experience from the venture capital industry. He has also been CEO of two MedTech companies and CFO of a wind power company. Per has been responsible for a large number of significant investments, fund raisings and exits, and has participated in six IPOs. Fredrik Järrsten has been CFO of the company since 2017 and Deputy CEO since 2019. In September 2020, the announced that he wished to leave his role to move on to a senior position in another life science company. He has remained at the company's continued disposal during the notice period to ensure a smooth transition.공시 • Feb 27Karolinska Development Appoints Johan Dighed as Deputy CEOKarolinska Development AB announced that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will, in addition to his new duties, continue to hold his current role as the company's General Counsel.공시 • Feb 20Karolinska Development AB (publ) Announces Management AppointmentsKarolinska Development AB (publ) held an Extraordinary General Meeting on February 19, 2021. At the Extraordinary General Meeting, it was resolved, in accordance with the Nomination Committee’s proposal, to elect Anna Lefevre Skjöldebrand and Ben Toogood as new directors, and to elect Björn Cochlovius as new chairman of the Board of Directors.Reported Earnings • Feb 12Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).Is New 90 Day High Low • Nov 19New 90-day low: €0.21The company is down 24% from its price of €0.27 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 29New 90-day low: €0.23The company is down 13% from its price of €0.26 on 31 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.공시 • Jul 31Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB.Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020. Karolinska Development AB (publ) has an option agreement to increase the ownership in Svenska Vaccinfabriken Produktion AB to a total of 25% within a defined period of time and at a predetermined price. Karolinska Development will be represented on the Svenska Vaccinfabriken Produktion AB Board of Directors. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020.매출 및 비용 세부 내역KDventures가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:2I9 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 262-21415031 Dec 252-19416030 Sep 252-13621030 Jun 252-8021031 Mar 252-2323031 Dec 242-825030 Sep 242-2922030 Jun 242-622031 Mar 2423423031 Dec 232522030 Sep 2321722030 Jun 232-4123031 Mar 232-8723031 Dec 222-8827030 Sep 222-11827030 Jun 222-7228031 Mar 22216627031 Dec 21217123030 Sep 21227621030 Jun 21210823031 Mar 212-10624031 Dec 203-20724030 Sep 2033526030 Jun 20319023031 Mar 20419524031 Dec 19330324030 Sep 194-1121030 Jun 194820031 Mar 1933216031 Dec 1833116030 Sep 1834820030 Jun 18323822031 Mar 18318524031 Dec 17218025030 Sep 17512523030 Jun 175-8722031 Mar 175-14220031 Dec 165-21719030 Sep 162-31524030 Jun 162-32525031 Mar 163-90429031 Dec 153-1,05533030 Sep 154-98041030 Jun 155-1,072510양질의 수익: 2I9 은(는) 현재 수익성이 없습니다.이익 마진 증가: 2I9는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 2I9은 수익성이 없으며 지난 5년 동안 손실이 연평균 48.3% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 2I9의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 2I9은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(15.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 2I9는 현재 수익성이 없으므로 자본 수익률이 음수(-19.35%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/17 16:19종가2026/06/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스KDventures AB는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Johan LöchenABG Sundal Collier SponsoredEspen JørgensenDNB CarnegieKlas PalinDNB Carnegie Commissioned Research1명의 분석가 더 보기
공시 • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026
Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.
공시 • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025
Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Karl Anders Harfstrand was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 07KDventures AB, Annual General Meeting, May 12, 2026KDventures AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: nanna svartz vag 2, 171 65 solna, solna Sweden
공시 • Mar 03KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian SyndromeKDventures AB announced that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition. In 2021, Organon acquired KDventures' portfolio company Forendo, but in July 2025 discontinued development of OG-6219, its most advanced drug candidate targeting endometriosis. The acquisition also included a preclinical drug candidate for polycystic ovary syndrome. Organon has now announced that development of this drug candidate has also been discontinued. This announcement means that the value of KDventures' share of the parties’ agreement on potential additional purchase considerations will be written off in its entirety, which will be reported in the interim report for the first quarter of 2026.
공시 • Jan 29Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 384,166,664 Price\Range: SEK 0.3 Transaction Features: Rights Offering
공시 • Dec 01Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 675,193,985 Price\Range: SEK 0.3 Transaction Features: Rights Offering
공시 • Nov 05Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemiaKarolinska Development AB announced that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in fourth quarter of 2025, in line with the company's development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of The company's phase 2 study with sevuparin in patients with chronic kidney disease with anemic. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated.
공시 • Sep 04Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million. Security Name: Shares Security Type: Common Stock Transaction Features: Rights Offering
공시 • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026
공시 • Jun 30An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025.
공시 • Apr 08Karolinska Development AB (publ), Annual General Meeting, May 15, 2025Karolinska Development AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at nanna svartz vag 2, 17165 solna, Sweden
공시 • Dec 19Karolinska Development AB Announces Changes to ChairmanKarolinska Development AB announced that its Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also Head of Global Business Development at Sino Pharmaceuticals Limited, CEO at invoX Pharma Limited and Director at Softhale BV and pHion Therapeutics.
공시 • Dec 11Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the BoardKarolinska Development AB announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting.
Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
공시 • Nov 15Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF VaccinesKarolinska Development AB announced that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15, 2024, as Dr Richard Bethell has decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role. Dr. Gaston Picchio has over 30 years of experience in clinical virology from his previous roles at the Scripps Research Institute, Johnson & Johnson, and Arbutus Biopharma. While at Johnson & Johnson, Dr. Picchio was involved in the development and approval of antivirals and vaccines for HIV, HCV, and Zika. Most recently, he comes from Arbutus Biopharma, where he led the development of novel therapeutic combinations aimed at curing chronic hepatitis B.
공시 • Sep 23An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024. An undisclosed buyer completed the acquisition of 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024.
Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 39 percentage points per year, which is a significant difference in performance.
공시 • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025
New Risk • May 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings are forecast to decline by an average of 72% per year for the foreseeable future. Revenue is less than US$1m (kr1.9m revenue, or US$184k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€36.7m market cap, or US$39.9m).
Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
공시 • Apr 16Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-ElectionKarolinska Development AB (publ) announced that Björn Cochlovius has declined re-election.
Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year.
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$191k). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€37.5m market cap, or US$40.5m).
Recent Insider Transactions • Feb 28Chief Executive Officer recently bought €7.2k worth of stockOn the 19th of February, Viktor Drvota bought around 50k shares on-market at roughly €0.14 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Viktor's only on-market trade for the last 12 months.
Reported Earnings • Feb 18Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 4% per year.
공시 • Feb 03+ 5 more updatesKarolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024Karolinska Development AB (publ) announced that they will report first half, 2024 results on Aug 30, 2024
New Risk • Nov 19New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 67% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 67% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$194k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€38.3m market cap, or US$41.8m).
공시 • Nov 09Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,150,000 Price\Range: SEK 2 Transaction Features: Rights Offering
공시 • Sep 21Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal SurgeryKarolinska Development AB announced that its portfolio company OssDsign has received clearance from FDA for the use of OssDsign Catalyst in interbody cages in spinal surgery. The FDA clearance creates possibilities in a new indication with major market potential for the company's innovative nanosynthetic bone graft. The clearance from the U.S. Food and Drug Administration (FDA) allows surgeons to use the OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone. The decision by the FDA is based on OssDsign's outstanding bone regeneration results which surpass other synthetic bone grafts in challenging evaluation models.
Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.086 (up from kr0.083 loss in 2Q 2022). Net income: kr23.3m (up kr45.6m from 2Q 2022). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.1%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
Reported Earnings • Mar 28Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr0.34 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 4.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.4%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 18Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr3.43 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 7.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.5%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
공시 • Feb 15Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive DataKarolinska Development AB (publ) announced that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate tafoxiparin has resulted in further positive data. The extension of the study met its objective, which was to evaluate if the efficacy of tafoxiparin obtained in the phase 2b trial persists when the drug is administered in additional doses. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. The completed extension of the phase 2b study included a total of 164 women, and the results show that the cervical ripening effect persists in the study. In addition, a clear dose-response relationship was observed. Up to 30% of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child, leading to high healthcare costs. Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%.
Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr46.6m (loss widened kr45.4m from 3Q 2021). Revenue is expected to decline by 3.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Germany are expected to grow by 3.9%.
공시 • Nov 19+ 1 more updateKarolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023Karolinska Development AB (publ) announced that they will report first half, 2023 results on Aug 25, 2023
공시 • Nov 18Karolinska Development AB (publ), Annual General Meeting, May 16, 2023Karolinska Development AB (publ), Annual General Meeting, May 16, 2023.
Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr22.3m (down 110% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 8.1% compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
공시 • Aug 19+ 2 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Karolinska Development AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023
Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr29.2m (loss widened 17% from 1Q 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 8.1% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
공시 • Apr 26Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion StudyKarolinska Development AB (publ) announced that its portfolio company OssDsign has enrolled all patients in the clinical study TOP FUSION, which will primarily evaluate the safety and efficacy of OssDsign Catalyst in patients undergoing spinal fusion surgery. OssDsign will now follow the patients recruited for the study for 24 months. The outcome of the study will primarily focus on healing between the vertebrae and the lack of treatment-related side effects. The company’s nanosynthetic bone graft OssDsign Catalyst received FDA approval in 2020 and was launched on the US market in August 2021. Karolinska Development's shareholding in OssDsign AB, including indirect ownership via KCIF Co-Investment Fund, amounts to 10.4%.
Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 7.8% compared to a 7.8% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
공시 • Feb 08Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 93,360,022 Price\Range: SEK 4 Security Name: Class A Shares Security Type: Common Stock Securities Offered: 1,052,163 Price\Range: SEK 4 Transaction Features: Rights Offering
공시 • Dec 14Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others.Organon & Co. (NYSE:OGN) agreed to acquire Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others for approximately $950 million on November 11, 2021. Under the agreement, Organon & Co. shall make an initial payment of $75 million. In addition, there are conditional payments totaling $270 million linked to milestones in the development and registration processes for the company's drug candidates, and additional payments totaling $600 million linked to commercial milestones. The completion of the transaction is subject to review by competition authorities and other customary conditions. The transaction is expected to close in December 2021. Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others on December 11, 2021. The consideration for the transaction includes a $75 million upfront payment, assumption of approximately $9 million of Forendo debt, payments upon the achievement of certain development and regulatory milestones of up to $270 million and commercial milestones payments of up to $600 million, which together could amount to total consideration of $954 million. Moelis & Company acted as exclusive financial advisor to Forendo.
공시 • Dec 02Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate SevuparinKarolinska Development AB (publ) announced that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of sevuparin. The drug candidate is being developed as a potential treatment for sepsis/septic shock, a serious and often fatal condition. The randomized, placebo-controlled Phase 1b study will evaluate the effect of sevuparin on symptoms in healthy individuals injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and in the blood (systemic inflammation). Provocation with LPS is a well-established experimental model to characterize the early stages of septic inflammation by eliciting measurable symptoms. In addition, the study will evaluate the safety profile of sevuparin when used in combination with standard prophylactic blood-thinning heparin therapy.
Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr1.20m (loss narrowed 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Nov 16Investor sentiment improved over the past weekAfter last week's 174% share price gain to €1.13, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 22x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 79% over the past three years.
Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)Second quarter 2021 results: Net income: kr216.4m (up kr214.3m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
공시 • Aug 13Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical ProgramKarolinska Development AB announced that the US Food and Drug Administration (FDA) has issued a clinical hold for Aprea Therapeutics clinical program evaluating eprenetapopt with acalabrutinib or venetoclax and rituximab in lymphoid malignancies. The issue means there will be a pause in the patient enrollment until the agency reverses the decision. Patients previously enrolled and showing positive clinical responses will continue to receive study treatment. Aprea Therapeutics was initially notified of a partial hold in the myeloid malignancy clinical program and shortly thereafter received notification from the FDA that a clinical hold had also been issued in the ongoing lymphoid malignancy study. The agency's decision is related to the safety and efficacy data presented in a recent Phase 3 study of eprenetapopt in TP53-mutaed myelodysplastic syndrome (MDS). Aprea Therapeutics intends to work in close dialogue with the FDA to clarify and address the agency's concerns in order to resume activity in the clinical trial program as soon as possible. Karolinska Development has an interest in Aprea Therapeutics through KDev Investment amounting to a total holding of 8.4% of the outstanding shares in Aprea Therapeutics.
공시 • Jun 18Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB.Karolinska Development AB (publ) (OM:KDEV) acquired 21% stake in Anacardio AB on June 17, 2021. The consideration received under the transaction is intended to cover costs for necessary activities prior to a planned major capital raising to finance the first part of the project's clinical development. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 21% stake in Anacardio AB on June 17, 2021.
Reported Earnings • May 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr24.9m (loss narrowed 80% from 1Q 2020).
Reported Earnings • Mar 31Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).
Executive Departure • Mar 10CFO & Deputy CEO Fredrik Jarrsten has left the companyOn the 7th of March, Fredrik Jarrsten, was replaced as CEO by Viktor Drvota. As of December 2020, Fredrik personally held only 120.00k shares (€19k worth at the time). A total of 5 executives have left over the last 12 months.
공시 • Mar 03+ 1 more updateKarolinska Development AB Announces CFO ChangesKarolinska Development AB announced that Per Aniansson has been appointed as new CFO. He has extensive experience in investments, business development and financing of high-growth companies in the life science industry. Per Aniansson takes up the position on March 7 and will initially work part-time (50%) in the company. He replaces Fredrik Järrsten, who has chosen to move on to a leading position within another life science company. Per Anainsson (b. 1966), Master of Science in Engineering and MBA, has over 20 years of experience from the venture capital industry. He has also been CEO of two MedTech companies and CFO of a wind power company. Per has been responsible for a large number of significant investments, fund raisings and exits, and has participated in six IPOs. Fredrik Järrsten has been CFO of the company since 2017 and Deputy CEO since 2019. In September 2020, the announced that he wished to leave his role to move on to a senior position in another life science company. He has remained at the company's continued disposal during the notice period to ensure a smooth transition.
공시 • Feb 27Karolinska Development Appoints Johan Dighed as Deputy CEOKarolinska Development AB announced that Johan Dighed has been appointed as Deputy CEO. He takes up the position immediately and will, in addition to his new duties, continue to hold his current role as the company's General Counsel.
공시 • Feb 20Karolinska Development AB (publ) Announces Management AppointmentsKarolinska Development AB (publ) held an Extraordinary General Meeting on February 19, 2021. At the Extraordinary General Meeting, it was resolved, in accordance with the Nomination Committee’s proposal, to elect Anna Lefevre Skjöldebrand and Ben Toogood as new directors, and to elect Björn Cochlovius as new chairman of the Board of Directors.
Reported Earnings • Feb 12Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019).
Is New 90 Day High Low • Nov 19New 90-day low: €0.21The company is down 24% from its price of €0.27 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 29New 90-day low: €0.23The company is down 13% from its price of €0.26 on 31 July 2020. The German market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
공시 • Jul 31Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB.Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020. Karolinska Development AB (publ) has an option agreement to increase the ownership in Svenska Vaccinfabriken Produktion AB to a total of 25% within a defined period of time and at a predetermined price. Karolinska Development will be represented on the Svenska Vaccinfabriken Produktion AB Board of Directors. Karolinska Development AB (publ) (OM:KDEV) completed the acquisition of 5% stake in Svenska Vaccinfabriken Produktion AB on March 27, 2020.